ZELBORAF Drug Patent Profile

Which patents cover Zelboraf, and when can generic versions of Zelboraf launch?

Zelboraf is a drug marketed by Hoffmann La Roche and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and ninety-five patent family members in forty-six countries.

The generic ingredient in ZELBORAF is vemurafenib. One supplier is listed for this compound. Additional details are available on the vemurafenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zelboraf

Zelboraf was eligible for patent challenges on August 17, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 6, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZELBORAF

International Patents:	195
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZELBORAF

ZELBORAF is protected by seven US patents.

This potential generic entry date is based on patent 9,447,089.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	8,470,818
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	7,504,509		Y	Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	9,447,089		Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	8,143,271		Y	Y

International Patents for ZELBORAF

When does loss-of-exclusivity occur for ZELBORAF?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Honduras

Hong Kong

Hungary

Israel

Japan

Jordan

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Peru

Poland

Portugal

Russian Federation

San Marino

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZELBORAF around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	I522337
Spain	2565992
Mexico	2012001463	PROCESO PARA LA FABRICACION DE COMPUESTOS. (PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS.)
Denmark	2462116

Supplementary Protection Certificates for ZELBORAF

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893612	SPC/GB12/021	United Kingdom		PRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/12/751/001 20120221
1893612	122 5012-2012	Slovakia		FIRST REGISTRATION NO/DATE: EU/1/12/751/001, 20120217
1893612	92035	Luxembourg		92035, EXPIRES: 20270217
1893612	462	Finland

Investment Scenario and Fundamentals Analysis for ZELBORAF (Vemurafenib)

Last updated: February 20, 2026

What is the current market and clinical position of ZELBORAF?

ZELBORAF (vemurafenib) is an FDA-approved BRAF inhibitor indicated primarily for BRAF V600 mutation-positive melanoma. It is marketed by Roche. Since its approval in 2011, ZELBORAF has captured significant market share in melanoma treatment and expanded into additional indications, including Erdheim-Chester disease and certain cases of hairy cell leukemia. The drug generated approximately $1.4 billion in global sales in 2022, reflecting steady revenue from established use and ongoing demand.

What are the key development and regulatory milestones?

Year	Milestone
2011	FDA approval for metastatic melanoma with BRAF V600E mutation.
2014	Approved for BRAF mutation-positive metastatic or unresectable melanoma in Europe.
2018	Expanded approval for use in combination with trametinib for BRAF V600 mutation-positive melanoma.
2020	FDA approval for use in Erdheim-Chester disease.
2022	Ongoing clinical trials for combination therapies and non-melanoma indications.

What are the market fundamentals driving investment?

• Market Size: The melanoma treatment market was estimated at $1.2 billion in 2022 globally, expected to grow at a compound annual growth rate (CAGR) of 8% through 2028. The expansion into non-melanoma indications provides additional revenue streams.
• Competitive Landscape: ZELBORAF faces competition from MEK inhibitors such as cobimetinib (GDC-0973) and encorafenib. Combination regimens remain dominant in advanced melanoma treatment with high prescription rates.
• Patent and Exclusivity: Roche holds composition of matter patents scheduled to expire around 2027-2029, with data exclusivity expected until 2032.
• Pricing: Average wholesale price (AWP) is approximately $15,000 per month per patient, with rebates and discounts influence net revenue.
• Market Penetration: In North America, ZELBORAF commands around 40% of the BRAF inhibitor segment for melanoma. Adoption in Europe is slightly lower due to regulatory delays and competitive products.

What are the clinical and pipeline prospects?

• Clinical Data: Phase III trials demonstrate improved progression-free survival (PFS) up to 7.4 months versus 1.6 months with chemotherapy in V600 mutation-positive melanoma.
• Combination Therapies: Trials combining ZELBORAF with MEK inhibitors (trametinib, binimetinib) show synergy, leading to longer PFS and overall survival (OS). These combinations are now first-line standards.
  • Example: COMBI-v trial recorded median OS of 25.9 months.
• Pipeline: Roche is testing ZELBORAF in combination with immunotherapies (e.g., checkpoint inhibitors) in ongoing trials to counter resistance mechanisms.
• Emerging Indications: Expanded use in non-melanoma cancers with BRAF mutations may unlock future markets, contingent on positive clinical data.

What are the risks and challenges?

• Resistance Development: Acquired resistance is common, limiting long-term efficacy.
• Toxicity: Cutaneous adverse events and secondary skin cancers affect adherence.
• Regulatory Risks: Delays or rejections in new indications could constrain growth.
• Patent Expiry: Loss of patent protection from 2027 may lead to generic competition, pressuring prices.

Investment outlook summary

Aspect	Outlook
Revenue Stability	Moderate, supported by first-line use and combination regimens.
Market Growth	Moderate growth forecast, driven by pipeline expansion and broader indications.
Competitive Pressure	High, particularly from combination regimens and alternative BRAF + MEK inhibitors.
Patent Cliff	Approaching in 2027–2029, necessitating pipeline and new indications to sustain revenue.
R&D Pipeline	Strong, with ongoing trials for combination strategies and non-melanoma indications.

Key Takeaways

• ZELBORAF remains a cornerstone BRAF inhibitor with established efficacy in melanoma.
• The drug's future depends on pipeline success, especially in combination therapies and new indications.
• Patent expiration poses a significant risk to revenue unless mitigated via product lifecycle strategies.
• Competition from emerging treatments and combination regimens constrains pricing power.
• Investment consideration requires monitoring of clinical trial outcomes and regulatory developments in new indications.

FAQs

1. What are the primary drivers of ZELBORAF’s revenue?
The drug’s key revenue source is its use in BRAF V600 mutation-positive melanoma, with growth from combination therapy adoption and new indications like Erdheim-Chester disease.

2. How does ZELBORAF compare with competitors?
It competes mainly with other BRAF inhibitors like dabrafenib and encorafenib, with combination therapies like dabrafenib/trametinib being predominant in the market.

3. What are the main regulatory risks?
Regulatory approval is contingent on clinical trial outcomes; failures in pipeline trials or delays in expanding indications can impact sales.

4. How imminent is patent expiry, and what are implications?
Patents are expiring between 2027 and 2029, risking generic entry and pricing pressures, unless Roche secures new patents or indications.

5. Which pipeline areas could significantly influence ZELBORAF’s valuation?
Combination therapy trials with immunotherapies and new non-melanoma BRAF-mutant cancers are high-priority areas with potential to extend product lifecycle.

---

References

[1] Roche. (2022). ZELBORAF (Vemurafenib) Prescribing Information.
[2] MarketWatch. (2023). Melanoma drugs market size and growth rate.
[3] FDA. (2011). Approval of ZELBORAF.
[4] ClinicalTrials.gov. (2023). ZELBORAF clinical trial portfolio.
[5] IQVIA. (2022). Worldwide Oncology Market Data.